Chapter 44 : Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816872/9781555815141_Chap44-1.gif /docserver/preview/fulltext/10.1128/9781555816872/9781555815141_Chap44-2.gif


Viruses that have evolved to frequently establish persistent infection are rarely successful targets for vaccine prevention. The clearest evidence that a virus is capable of significant immune evasion is whether or not the host can be reinfected. This review discusses the immunobiology of human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV), and respiratory syncytial virus, which have evaded vaccine development. The chapter also talks about potential solutions for the elusive viral pathogens. Infection is self-limited in some individuals, suggesting that immunity is sometimes effective. Features that distinguish successful immune responses from failed responses to HCV have not yet been identified, thus complicating vaccine development. HIV-1 and HCV display extreme genetic diversity, more than any other known viral pathogen. Prior to discovery of the highly mutable RNA viruses in the 1980s, influenza had been the prototype of a viral vaccine target with genetic variation occurring through both point mutations and reassortment of genes. For HIV and HCV viruses, defining the breadth of response, the number of epitope responses needed for each incoming virus, and the extent of cross-reactive responses needed to defend against the diversity of potential infecting stains are important for the next generation of T-cell-based vaccines. The focus on early infection events should include intensive characterization of viruses that make it through the bottleneck described for transmission. This could significantly simplify the complexity of the antigenic content currently thought to be required for a preventive vaccine.

Citation: Graham B, Walker C. 2011. Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, p 559-570. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch44

Key Concept Ranking

Human immunodeficiency virus 1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Immune strategies for coping with genetic diversity. The immune system is designed to accommodate genetic diversity among individuals and genetic diversity of microbes. T-cell epitopes are relatively conserved across viral subtypes compared to antibody epitopes. The implication is that vaccine-induced T-cell mechanisms may be of particular value for highly diverse viruses. Conversely, antibody-mediated protection against a specific structure may be achievable across diverse population groups.

Citation: Graham B, Walker C. 2011. Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, p 559-570. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Evolution of viral vaccines. The 15 available antiviral vaccines have taken over 200 years to develop. Most of the rapid advances have followed the emergence of new technologies that made vaccine development possible. Vaccines developed because of the discovery of cell culture and the ability to propagate viruses in vitro are noted in green. Vaccines developed as a consequence of tools made available by molecular biology are noted in red. Rapid advances in fields ranging from genetics to computational biology may open new possibilities for developing vaccines against difficult and emerging viral pathogens. The list of future technologies is to suggest areas in which technical advances may provide an impetus for development.

Citation: Graham B, Walker C. 2011. Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, p 559-570. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Barouch,, D. H.,, J. Kunstman,, M. J Kuroda,, J. E. Schmitz,, S. Santra,, F. W. Peyerl,, G. R. Krivulka,, K. Beaudry,, M. A. Lifton,, D. A. Gorgone,, D. C. Montefiori,, M. G. Lewis,, S. M. Wolinsky, and, N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335339.
2. Bassett,, S. E.,, B. Guerra,, K. Brasky,, E. Miskovsky,, M. Houghton,, G. R Klimpel, and, R. E. Lanford. 2001. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33:14791487.
3. Blankson, J. N., D. Persaud, and, R. F. Siliciano. 2002. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53:557593.
4. Bowen, D. G., and, C. M. Walker. 2005a. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946952.
5. Bowen, D. G., and, C. M. Walker. 2005b. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J. Exp. Med. 201:17091714.
6. Brenchley, J. M., and, D. C. Douek. 2008. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3:35661.
7. Brenchley,, J. M.,, D. A. Price,, T. W. Schacker,, T. E. Asher,, G. Silvestri,, S. Rao,, Z. Kazzaz,, E. Bornstein,, O. Lambotte,, D. Altmann,, B. R. Blazar,, B. Rodriguez,, L. Teixeira-Johnson,, A. Landay,, J. N. Martin,, F. M. Hecht,, L. J. Picker,, M. M. Lederman,, S. G. Deeks, and, D. C. Douek. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:13651371.
8. Buchbinder, S. P.,, D. V. Mehrotra,, A. Duerr,, D. W Fitzgerald,, R. Mogg,, D. Li,, P. B. Gilbert,, J. R. Lama,, M. Marmor,, C. Del Rio,, M. J. McElrath,, D. R. Casimiro,, K. M. Gottesdiener,, J. A. Chodakewitz,, L. Corey, and, M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:18811893.
9. Bukh,, J., R. Thimme,, J. C. Meunier,, K. Faulk,, H. C Spangenberg,, K. M Chang,, W. Satterfield,, F. V. Chisari, and, R. H. Purcell. 2008. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82:81838195.
10. Burton,, D. R.,, R. C. Desrosiers,, R. W. Doms,, W. C. Koff,, P. D. Kwong,, J. P. Moore,, G. J. Nabel,, J. Sodroski,, I. A. Wilson, and, R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233236.
11. Carrington, M.,, G. W. Nelson,, M. P. Martin,, T. Kissner,, D. Vlahov,, J. J Goedert,, R. Kaslow,, S. Buchbinder,, K. Hoots, and, S. J. O’Brien. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:17481752.
12. Carrington, M., and, S. J. O’Brien. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535551.
13. Coleman, C. M., and, L. Wu. 2009. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6:51.
14. Delgado,, M. F.,, S. Coviello,, A. C Monsalvo,, G. A. Melendi,, J. Z. Hernandez,, J. P. Batalle,, L. Diaz,, A. Trento,, H. Y. Chang,, W. Mitzner,, J. Ravetch,, J. A. Melero,, P. M. Irusta, and, F. P. Polack. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:3441.
15. Douek, D. C., L. J. Picker, and, R. A. Koup. 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21:265304.
16. Farci, P.,, H. J. Alter,, D. C. Wong,, R. H. Miller,, S. Govindarajan,, R. Engle,, M. Shapiro, and, R. H. Purcell. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibodymediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91:77927796.
17. Finzi, D.,, J. Blankson,, J. D. Siliciano,, J. B. Margolick,, K. Chadwick,, T. Pierson,, K. Smith,, J. Lisziewicz,, F. Lori,, C. Flexner,, T. C. Quinn,, R. E. Chaisson,, E. Rosenberg,, B. Walker,, S. Gange,, J. Gallant, and, R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512517.
18. Fischer,, W., S. Perkins,, J. Theiler,, T. Bhattacharya,, K. Yusim,, R. Funkhouser,, C. Kuiken,, B. Haynes,, N. L. Letvin,, B. D. Walker,, B. H. Hahn, and, B. T. Korber. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100106.
19. Folgori,, A., S. Capone,, L. Ruggeri,, A. Meola,, E. Sporeno,, B. B. Ercole,, M. Pezzanera,, R. Tafi,, M. Arcuri,, E. Fattori,, A. Lahm,, A. Luzzago,, A. Vitelli,, S. Colloca,, R. Cortese, and, A. Nicosia. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12:190197.
20. Gale, M., Jr., and, E. M. Foy. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436:939945.
21. Goepfert,, P. A.,, W. Lumm,, P. Farmer,, P. Matthews,, A. Prendergast,, J. M Carlson,, C. A Derdeyn,, J. Tang,, R. A. Kaslow,, A. Bansal,, K. Yusim,, D. Heckerman,, J. Mulenga,, S. Allen,, P. J. Goulder, and, E. Hunter. 2008. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205:10091017.
22. Graham,, B. S.,, G. S. Henderson,, Y. W. Tang,, X. Lu,, K. M. Neuzil, and, D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:20322040.
23. Graham, B. S., J. E. Ledgerwood, and, G. J. Nabel. 2009. Vaccine development in the twenty-first century: changing paradigms for elusive viruses. Clin. Pharmacol. Ther. 86:2346.
24. Gray, R. H.,, M. J. Wawer,, R. Brookmeyer,, N. K Sewankambo,, D. Serwadda,, F. Wabwire-Mangen,, T. Lutalo,, X. Li,, T. vanCott, and, T. C. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:11491153.
25. Haaland,, R. E.,, P. A. Hawkins,, J. Salazar-Gonzalez,, A. Johnson,, A. Tichacek,, E. Karita,, O. Manigart,, J. Mulenga,, B. F. Keele,, G. M. Shaw,, B. H. Hahn,, S. A. Allen,, C. A. Derdeyn, and, E. Hunter. 2009. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5:e1000274.
26. Hall,, C. B.,, E. E. Walsh,, C. E. Long, and, K. C. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693698.
27. Houghton, M., and, S. Abrignani. 2005. Prospects for a vaccine against the hepatitis C virus. Nature 436:961966.
28. Hutter,, G., D. Nowak,, M. Mossner,, S. Ganepola,, A. Mussig,, K. Allers,, T. Schneider,, J. Hofmann,, C. Kucherer,, O. Blau,, I. W. Blau,, W. K. Hofmann, and, E. Thiel. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stemcell transplantation. N. Engl. J. Med. 360:692698.
29. Keele,, B. F.,, L. Tazi,, S. Gartner,, Y. Liu,, T. B Burgon,, J. D Estes,, T. C. Thacker,, K. A. Crandall,, J. C. McArthur, and, G. F. Burton. 2008. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 82:55485561.
30. Korber, B.,, B. Gaschen,, K. Yusim,, R. Thakallapally,, C. Kesmir, and, V. Detours. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58:1942.
31. Koup, R. A.,, J. T. Safrit,, Y. Cao,, C. A Andrews,, G. McLeod,, W. Borkowsky,, C. Farthing, and, D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:46504655.
32. Kwong, P. D., and, I. A. Wilson. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10:573578.
33. Law,, M., T. Maruyama,, J. Lewis,, E. Giang,, A. W. Tarr,, Z. Stamataki,, P. Gastaminza,, F. V. Chisari,, I. M. Jones,, R. I. Fox,, J. K. Ball,, J. A. McKeating,, N. M. Kneteman, and, D. R. Burton. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:2527.
34. Letvin,, N. L.,, J. R. Mascola,, Y. Sun,, D. A Gorgone,, A. P Buzby,, L. Xu,, Z. Y. Yang,, B. Chakrabarti,, S. S. Rao,, J. E. Schmitz,, D. C. Montefiori,, B. R. Barker,, F. L. Bookstein, and, G. J. Nabel. 2006. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:15301533.
35. Li,, Y.,, S. A. Migueles,, B. Welcher,, K. Svehla,, A. Phogat,, M. K Louder,, X. Wu,, G. M. Shaw,, M. Connors,, R. T. Wyatt, and, J. R. Mascola. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:10321034.
36. Major,, M. E.,, K. Mihalik,, M. Puig,, B. Rehermann,, M. Nascimbeni,, C. M Rice, and, S. M. Feinstone. 2002. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76:65866595.
37. Mascola, J. R.,, G. Stiegler,, T. C VanCott,, H. Katinger,, C. B. Carpenter,, C. E. Hanson,, H. Beary,, D. Hayes,, S. S. Frankel,, D. L. Birx, and, M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207210.
38. McCutchan, F. E. 2000. Understanding the genetic diversity of HIV-1. AIDS 14:S31S44.
39. McElrath,, M. J.,, S. C. De Rosa,, Z. Moodie,, S. Dubey,, L. Kierstead,, H. Janes,, O. D. Defawe,, D. K. Carter,, J. Hural,, R. Akondy,, S. P. Buchbinder,, M. N. Robertson,, D. V. Mehrotra,, S. G. Self,, L. Corey,, J. W. Shiver, and, D. R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:18941905.
40. McLellan,, J. S.,, M. Chen,, A. Kim,, Y. Yang,, B. S Graham, and, P. D. Kwong. 2010. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17:248250.
41. Moir, S., and, A. S. Fauci. 2009. B cells in HIV infection and disease. Nat. Rev. Immunol. 9:235245.
42. Musey,, L., Y. Ding,, M. Elizaga,, R. Ha,, C. Celum, and, M. J. McElrath. 2003. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J. Immunol. 171:10941101.
43. Osburn,, W. O.,, B. E. Fisher,, K. A. Dowd,, G. Urban,, L. Liu,, S. C. Ray,, D. L. Thomas, and, A. L. Cox. 2009. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138:315324.
44. Oshansky, C. M.,, W. Zhang,, E. Moore, and, R. A. Tripp. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4:279297.
45. Petrovas,, C., B. Chaon,, D. R. Ambrozak,, D. A. Price,, J. J. Melenhorst,, B. J. Hill,, C. Geldmacher,, J. P. Casazza,, P. K. Chattopadhyay,, M. Roederer,, D. C. Douek,, Y. M. Mueller,, J. M. Jacobson,, V. Kulkarni,, B. K. Felber,, G. N. Pavlakis,, P. D. Katsikis, and, R. A. Koup. 2009. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J. Immunol. 183:11201132.
46. Ray, S. C.,, Thomas, D. L. 2009. Hepatitis C, p. 2157-2185. In G. L. Mandell,, J. E. Bennett,, R. Dolin, R. (ed.), Principles and Practice of Infectious Diseases, 7th ed. Churchill Livingstone, Philadelphia, PA.
47. Rehermann, B. 2009. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119:17451754.
48. Rerks-Ngarm, S.,, P. Pitisuttithum,, S. Nitayaphan,, J. Kaewkungwal,, J. Chiu,, R. Paris,, N. Premsri,, C. Namwat,, M. de Souza,, E. Adams,, M. Benenson,, S. Guruathan,, J. Tartaglia,, J. G. McNeil,, D. P. Francis,, D. Stablein,, D. L. Birx,, S. Chunsuttiwat,, C. Khamboonruang,, P. Thongcharoen,, M. L. Robb,, N. L. Michael,, P. Kunasol, and, J. H. Kim. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:22092220.
49. Rollier,, C. S.,, G. Paranhos-Baccala,, E. J. J,, B. E. Verstrepen,, J. A. Drexhage,, Z. Fagrouch,, J. L. Berland,, F. Komurian-Pradel,, B. Duverger,, N. Himoudi,, C. Staib,, M. Meyr,, M. Whelan,, J. A. Whelan,, V. C. Adams,, E. Larrea,, J. I. Riezu,, J. J. Lasarte,, B. Bartosch,, F. L. Cosset,, W. J. Spaan,, H. M. Diepolder,, G. R. Pape,, G. Sutter,, G. Inchauspe, and, J. L. Heeney. 2007. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45:602613.
50. Sabin, A. B. 1992. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc. Natl. Acad. Sci. USA 89:88528855.
51. Smith, D. M., D. D. Richman, and, S. J. Little. 2005. HIV superinfection. J. Infect. Dis. 192:438444.
52. Stamataki, Z.,, J. Grove,, P. Balfe, and, J. A. McKeating. 2008. Hepatitis C virus entry and neutralization. Clin. Liver Dis. 12:693712.
53. Sterling,, T. R.,, D. Vlahov,, J. Astemborski,, D. R. Hoover,, J. B. Margolick, and, T. C. Quinn. 2001. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N. Engl. J. Med. 344:720725.
54. Thongcharoen,, P., V. Suriyanon,, R. M. Paris,, C. Khamboonruang, M. S. de Souza, S. Ratto-Kim,, C. Karnasuta,, V. R. Polonis,, L. Baglyos,, R. E. Habib,, S. Gurunathan,, S. Barnett,, A. E. Brown,, D. L. Birx,, J. G. McNeil, and, J. H. Kim. 2007. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46:4855.
55. Uebelhoer,, L.,, J. H. Han,, B. Callendret,, G. Mateu,, N. H. Shoukry,, H. L. Hanson,, C. M. Rice,, C. M. Walker, and, A. Grakoui. 2008. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4:e1000143.
56. Veazey,, R. S.,, M. DeMaria,, L. V. Chalifoux,, D. E. Shvetz,, D. R. Pauley,, H. L. Knight,, M. Rosenzweig,, R. P. Johnson,, R. C. Desrosiers, and, A. A. Lackner. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427431.
57. Walker,, L. M.,, S. K. Phogat,, P. Y. Chan-Hui,, D. Wagner,, P. Phung,, J. L. Goss,, T. Wrin,, M. D. Simek,, S. Fling,, J. L. Mitcham,, J. K. Priddy,, O. A. Olsen,, S. M. Frey,, P. W. Hammond,, S. Kaminsky,, T. Zamb,, M. Moyle,, W. C. Koff,, P. Poignard, and, D. R. Burton. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285289.
58. Williams, J. V.,, J. H. Weitkamp,, D. L. Blum,, B. J. LaFleur, and, J. E. Crowe, Jr. 2009. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol. Immunol. 47:407414.
59. Wu, X.,, Y. Yang,, C. M. Hogerkosp,, W. R. Schief,, M. S. Seamen,, T. Zhou,, S. D. Schmidt,, L. Wu,, L. Xu,, N. S. Longo,, K. McKee,, S. O’Dell,, M. K. Louder,, D. L. Wycuff,, Y. Feng,, M. Nason,, N. Doria-Rose,, M. Connors,, P. D. Kwong,, M. Roederer,, R. T. Wyatt,, G. J. Nabel, and, J. R. Mascola. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856861.


Generic image for table

Characteristics of difficult viruses and those with successful preventive vaccines

Citation: Graham B, Walker C. 2011. Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, p 559-570. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch44
Generic image for table

Biological challenges for HIV vaccine development

Citation: Graham B, Walker C. 2011. Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses, p 559-570. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch44

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error